Literature DB >> 34050748

NIAID ClinRegs-a Public Database of Country Clinical Research Regulatory and Ethics Requirements: Design and Utilization Analysis.

Jonathan Kagan1, Geoffrey N Goodman2, Rachel Oh2, Diane Whitworth2, Darcie Gladden2, Gail Graves2, Antonia Nguyen2, Orish Shrestha2, Gerald Burge3, Mary Smolskis1, Janet Andrews4, Brian Cramer2, H Clifford Lane1.   

Abstract

Regulatory compliance is challenging for multinational clinical trials. Conflicts between country requirements impedes research and slows the approval of medicines, leading the pharmaceutical industry to devote significant resources to this area. Many academic centers and nonprofits cannot support industry-level investment and are vulnerable to noncompliance. To address an insufficiency in public access to this information, the National Institute of Allergy and Infectious Diseases developed ClinRegs-a public access database of clinical research regulations. This report describes ClinRegs' features, maintenance, and usage. From September 2019 through August 2020, ClinRegs had 68 504 users, 60% from outside the United States, demonstrating the demand for accessible, reliable, country-specific regulatory information. Tools such as ClinRegs can help increase regulatory compliance and free up resources for research. We encourage our partner agencies and biomedical research industries to promote greater regulatory knowledge sharing and harmonization for the betterment of clinical research and improved public health. Published by Oxford University Press for the Infectious Diseases Society of America 2021.

Entities:  

Keywords:  clinical research quality; clinical research regulations; clinical trial ethics; global clinical trials; public access

Mesh:

Year:  2021        PMID: 34050748      PMCID: PMC8492127          DOI: 10.1093/cid/ciab505

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  5 in total

1.  Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health.

Authors:  James D Neaton; Abdel Babiker; Mark Bohnhorst; Janet Darbyshire; Eileen Denning; Arnie Frishman; Jesper Grarup; Gregg Larson; Jens Lundgren
Journal:  Clin Trials       Date:  2010-08-20       Impact factor: 2.486

2.  Clinical trials bureaucracy: unintended consequences of well-intentioned policy.

Authors:  Robert M Califf
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

3.  Specific barriers to the conduct of randomized trials.

Authors:  Lelia Duley; Karen Antman; Joseph Arena; Alvaro Avezum; Mel Blumenthal; Jackie Bosch; Sue Chrolavicius; Timoa Li; Stephanie Ounpuu; Analia Cristina Perez; Peter Sleight; Robbyna Svard; Robert Temple; Yannis Tsouderous; Carla Yunis; Salim Yusuf
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

4.  Increasing value and reducing waste in biomedical research regulation and management.

Authors:  Rustam Al-Shahi Salman; Elaine Beller; Jonathan Kagan; Elina Hemminki; Robert S Phillips; Julian Savulescu; Malcolm Macleod; Janet Wisely; Iain Chalmers
Journal:  Lancet       Date:  2014-01-08       Impact factor: 79.321

Review 5.  Quality in the pharmaceutical industry - A literature review.

Authors:  Reham M Haleem; Maissa Y Salem; Faten A Fatahallah; Laila E Abdelfattah
Journal:  Saudi Pharm J       Date:  2013-11-20       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.